DelveInsight launched a new report on COVID 19 Therapeutic Pipeline, COVID 19 Vaccines, COVID 19 Diagnostics Competitive Landscape.
COVID 19 is a respiratory viral infection, in which common signs of infection include respiratory symptoms, fever, and cough, shortness of breath and breathing difficulties. In more severe cases, the infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death.
The recent report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the COVID- 19 pipeline. A detailed picture of the COVID-19pipeline landscape is provided, which includes the disease overview and COVID-19treatment guidelines specific to the country. The assessment part of the report elucidates in-depth COVID 19 clinical assessment of the COVID-19pipeline products from the pre-clinical developmental phase to the advanced phase.
In the COVID-19 report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, along with COVID 19 collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Request for free sample pages of the report: https://www.delveinsight.com/sample-request/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape
COVID19 Treatment Outlook:
Companies such as Gilead Sciences, Roche, Sanofi, Regeneron Moderna, Novavax, Medicago Inc., Altimmune, APEIRON Biologics, Inovio Pharmaceuticals, and GlaxoSmithKline are a few of the players working towards developing therapies for COVID-19.
Scope of the Report
- The report builds an understanding of the technologies and techniques being used to develop -COVID 19 treatment drugs and vaccines.
- Comprehensive insights into the pipeline products. The report provides detailed profiles of the pipeline assets and comparative analysis of clinical and non-clinical stage products.
- Assessment of active pipeline assets segmented by stage, product type, route of administration, and molecule type
- The report builds understanding of the insights about the pipeline drugs including the product-related agreements, collaborations, licensing, deals, and technology
COVID 19 Analytical Perspective by DelveInsight
The report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, fundings, etc. in a detailed manner.
Table of Contents:
1. Key Insights
2. Coronavirus Disease 2019 (COVID 19) Overview at a Glance
3. Disease Background and Overview: Coronavirus Disease 2019 (COVID 19)
5. Current Treatment Practices
6. COVID 19 – DelveInsight’s Analytical Perspective
7. Current Trends
8. Emerging Therapies
9. Therapeutic Assessment
10. Key Trends and Developments
11. SWOT Analysis
12. Market Drivers of COVID 19
13. Market Barriers of COVID 19
14. COVID 19 Unmet Needs
15. Analyst Review
17. DelveInsight Capabilities
19. About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States